Journal Article Summary
The article investigates the use of bridging anticoagulation therapy in patients with atrial fibrillation (AF) who are treated with warfarin and undergo surgical procedures. This topic is significant because warfarin is commonly prescribed to reduce the risk of stroke in AF patients, but it must be paused before surgery to prevent excessive bleeding. Bridging anticoagulation, typically with low-molecular-weight heparin (LMWH), is often used during this gap to mitigate stroke risk. However, the BRIDGE trial published in 2015 indicated that bridging LMWH did not significantly lower post-procedure stroke rates and increased bleeding risks, prompting the authors to examine how this trial's findings influenced clinical practice across the United States.
The researchers conducted a retrospective study using a large insurance claims database, focusing on adult patients with AF who were treated with warfarin and underwent various surgical procedures from July 2010 to November 2017. They analyzed the trends in LMWH use before and after the BRIDGE trial's publication. The study included 9,278 patients and found that the use of bridging LMWH decreased by approximately 6.7% after the trial, with a more significant decline observed in patients at moderate to high stroke risk. Factors such as younger age and the absence of diabetes were associated with a higher likelihood of receiving bridging LMWH.
Despite the study's strengths, including a large sample size, there are limitations to consider. The retrospective nature of the analysis means it can only show associations rather than causation, and certain clinical details may not have been captured in the claims data. Patients should discuss their individual risks and benefits regarding bridging anticoagulation with their healthcare providers, especially considering the potential for bleeding and thromboembolic events. Understanding these nuances is crucial for making informed decisions about anticoagulation management during surgical procedures.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Barnes Geoffrey D, Seiler Kristian, Brady Patrick, Kamdar Neil. Nation-wide Use of Periprocedural Bridging Anticoagulation in Patients with Atrial Fibrillation. The American journal of cardiology 2019. DOI: 10.1016/j.amjcard.2019.08.020. PMID: 31543215. PMCID: PMC6825891.
Featured Pill Pals Product
Warfarin 7.5 mg Tablets --- Generic For Coumadin --- Amneal
Warfarin 7.5 mg Tablets — Generic For Coumadin — Amneal is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
